EMEA-002299-PIP01-17
Key facts
| Active substance |
Enfortumab vedotin
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0114/2018
|
| PIP number |
EMEA-002299-PIP01-17
|
| Pharmaceutical form(s) |
Powder and solvent for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of urothelial carcinoma
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Astellas Pharma Europe B.V.
Tel.: +31 715455878
e-mail: contact@nl.astellas.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|